Cell Culture Media Market is Estimated to Reach USD 12.47 Billion by 2032 | MRFR

The cell culture media market is estimated to register a CAGR of 14.21% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the Global Cell Culture Media Market— Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Merck KGaA (Germany), Danaher Corporation (US), Lonza (Switzerland), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), Promocell GmbH (Germany), and Bio-Rad Laboratories, Inc. (US).

Market Highlights

The global cell culture media market is expected to register a CAGR of 14.21% during the forecast period and is estimated to reach USD 12.47 billion by 2032.

The growth of the cell culture media market is attributed to the strategic initiatives to boost pharmaceutical R&D, cell culture media associated product launch & investment, and the increasing incidences of chronic diseases. Moreover, cell culture media is a method used in the life sciences to encourage the development of cells and microorganisms. The term "cell culture media" alludes to a growth agent that is necessary for cell cultures to develop and endure under circumstances. Numerous substances are used to encourage cell development, including amino acids, glucose, serum, and inorganic salts. Furthermore, the pH balance of the cultured cells is also maintained by the cell culture fluid.

Strategic initiatives to boost pharmaceutical R&D is one of the imperative factors driving the growth of the global cell culture media market. Likewise, product launch & investment and increasing incidences of chronic diseases are propelling the growth of the global cell culture media market during the forecast period. However, the high cost of cell culture media and cell culture contamination is expected to hamper the growth of the global cell culture media market. Nonetheless, it is anticipated that frequent infectious disease outbreaks and private and public organizations pharmaceutical R&D strategy will create lucrative opportunities for the players operating in the global market.

Segment Analysis

The global cell culture media market has been segmented based on Product Type, Application, and Cell Type.

On the basis of product type, the market is segmented into media and supplements. The media segment held the majority share in the market in 2022. The media segment is further sub-segmented into basal media, complex media, and serum-free while the supplements segment is sub-segmented into Fetal Bovine Serum (FBS), newborn calf serum, horse serum, and others. Moreover, the growing prevalence of chronic diseases and rising adoption of 3D cell culture will help this segment to grow.

On the basis of the application, the market is segmented into regenerative medicine, biopharmaceutical production, and research. The biopharmaceutical production segment held the largest market share in 2022. The biopharmaceutical production segment is further bifurcated into monoclonal antibodies, vaccines, and others. Cell cultures form the base for the Biopharmaceutical production of many large molecule-based drugs, vaccines, and cellular therapies where cell culture media is used.

On the basis of cell type, the market is segmented into animal cells, plant cells, and bacterial cells. The bacterial cells segment held the majority share in the market in 2022. The bacterial cultures are used for recombinant protein expression, plasmid cloning and amplification, and bacterial artificial chromosome (BAC) and cosmid cloning. Bacterial cells can be altered to uptake and incorporate exogenous genes and plasmids through transformation. These factors are expected to collectively boost the segments growth.

Access full report @ https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

Regional Analysis

The global cell culture media market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe cell culture media market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The cell culture media market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World cell culture media market comprises of Middle East, Africa, and Latin America.

The presence of major market players in the North America region involved in product innovation, expansions, strategic collaborations, and well-developed healthcare infrastructure are contributing to the market growth. For instance, in November 2020, the Canadian Institutes of Health Research announced investing more than USD 30 million over the next seven years, starting from 2020-2021, in a new research project. This project will be part of the initiative ‘100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes. This will accelerate the development of stem cell-based therapies for treating Type 1 diabetes. Thus, above mentioned factors will help to propel market growth.

Europe accounts for the second-largest market share due to the boost in the biopharmaceutical sector in the European region, rising government initiatives to promote research to find a cure to the increasing number of chronic diseases, an increasing number of pharmaceutical manufacturers, improving economies, high disposable income per individual, and increased healthcare spending are driving the demand for cell culture media in Europe. Further, growing R&D activities and the developing biopharmaceutical sector are expected to drive the European market. For instance, according to the European Commission, gross domestic expenditure on R&D was USD 356.99 billion in 2021. The availability of high-end technologies in countries like Germany and growing funding from various public and private sources to conduct advanced research are fostering market growth.

Asia-Pacific is anticipated to register the highest growth rate over the forecast period. This is due to the presence of many research organizations, low manufacturing cost, low labor cost, developing healthcare infrastructure, and increased investments by the American and European market giants in Asian countries such as China and India are likely to drive the demand for cell culture media in the Asia-Pacific region. India’s cost of drug production is nearly 33 % lower than that of the US. For instance, according to the India Brand Equity Foundation, India is becoming a leading destination for clinical trials and contract research, and manufacturing activities. India’s cost of drug production is nearly 33 percent lower than that of the US. According to the World Bank, East Asia & Pacific had increased its R&D expenditure to 4.00% of GDP in 2022. Thus, these factors are likely to be responsible for the fastest growth of the Asia-Pacific region during the forecast period.

Moreover, the Rest of the World is segmented into the Middle East, Africa, and Latin America. The cell culture media market in the above-mentioned regions is likely to witness growth due to the increasing number of research companies and subsidiaries involved in R&D, and increasing initiatives are taken by Middle East countries to develop their healthcare infrastructure. Moreover, growing awareness and demand from the general population for effective treatments are likely to favor market growth.

Key Findings of the Study

• The global cell culture media market is expected to reach USD 12.47 billion by 2032, at a CAGR of 14.21% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market.


• Based on product type, the media segment was attributed to holding the largest market in 2022.


• Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Merck KGaA (Germany), Danaher Corporation (US), and Lonza (Switzerland) are the key market players.